Related Experiment Video

Updated: Jun 10, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

793

The Effect of Antiplatelet Therapy on COVID-19

Ecaterina Scarlatescu, Toshiaki Iba

    Juntendo Iji Zasshi = Juntendo Medical Journal
    |October 21, 2024
    PubMed

    Insights

    SARS-CoV-2 affects platelets, increasing thrombosis risk in COVID-19. Antiplatelet therapy may succeed if initiated early in moderate cases, warranting future clinical trials.

    Area of Science:

    • Hematology
    • Virology
    • Cardiovascular Medicine

    Background:

    • SARS-CoV-2 infection significantly impacts platelet function.
    • Activated platelets contribute to the prothrombotic state observed in COVID-19 patients.
    • Current international guidelines do not recommend antiplatelet therapy for COVID-19.

    Purpose of the Study:

    • To analyze the role of platelets in COVID-19-associated thrombosis.
    • To investigate the potential efficacy of antiplatelet therapy in COVID-19.
    • To identify optimal conditions for antithrombotic therapy in COVID-19.

    Main Methods:

    • Review of existing clinical studies on COVID-19 and thrombosis.
    • Analysis of platelet activation pathways in SARS-CoV-2 infection.
    • Comparison with clinical trial outcomes for anticoagulant therapies.

    Main Results:

    • Platelet activation by SARS-CoV-2 leads to prothrombotic substance release and coagulation activation.
    • Existing clinical trials for antiplatelet therapy in COVID-19 have yielded inconclusive results.
    • Anticoagulant therapy studies suggest early initiation in moderate-severity cases is crucial for success.

    Conclusions:

    • The timing of initiation and target patient severity are critical factors for the success of antiplatelet therapy in COVID-19.
    • Future clinical trials should explore antiplatelet interventions in carefully selected COVID-19 patient populations, focusing on early treatment in moderate disease.
    • Optimizing antithrombotic strategies, including antiplatelet agents, requires further investigation in specific COVID-19 contexts.

    Keywords:
    COVID-19P2Y12 inhibitoraspirinplateletthrombosis

    More Related Videos

    Ferric Chloride-induced Murine Thrombosis Models10:37

    Ferric Chloride-induced Murine Thrombosis Models

    Published on: September 5, 2016

    21.5K
    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

    4.8K

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    478
    Coronary Artery Disease V: Surgical Management01:27

    Coronary Artery Disease V: Surgical Management

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    3
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    625
    Formation of the Platelet Plug01:22

    Formation of the Platelet Plug

    The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
    As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
    4.8K
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    2
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    1.2K